[A25-51] Ribociclib (breast cancer, adjuvant treatment) – Addendum to Project A24-124
Last updated 05.06.2025
Project no.:
A25-51
Commission:
Commission awarded on 23.04.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adjuvant treatment of patients with HR-positive, HER2-negative early breast cancer at high risk of recurrence
Result of dossier assessment:
- Premenopausal women: added benefit not proven
- Postmenopausal women: hint of lesser benefit
- Men: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A25-51
| Project no. | Title | Status |
|---|---|---|
| A24-124 | Ribociclib (breast cancer, adjuvant treatment) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-06-05 A G-BA decision was published.